Preparation of high-performance ultrafine budesonide particles for pulmonary drug delivery

Chemical Engineering Journal

Volumn 252, Issue , 2014, Pages 281-287

  Xu, Li Min ^a   Hu, Ting Ting ^a,b   Pu, Yuan ^a   Le, Yuan ^a   Chen, Jian Feng ^a   Wang, Jie Xin ^a  

^a BEIJING UNIVERSITY OF CHEMICAL TECHNOLOGY   (China)

^b Beijing Aerospace Petrochemical Technology and Equipment Engineering Corporation   (China)

Author keywords

Budesonide; Dry powder aerosols; High pressure homogenization; Pulmonary drug delivery; Spray drying

Indexed keywords

AEROSOLS; AGGLOMERATION; SPRAY DRYING;

BUDESONIDE; CRYSTALLINE STRUCTURE; DRY POWDERS; HIGH PRESSURE HOMOGENIZATION; HIGH PRESSURE HOMOGENIZER; PARTICLE CONCENTRATIONS; PHARMACEUTICAL PRODUCTS; PULMONARY DRUG DELIVERY;

DRUG PRODUCTS;

EID: 84901653726     PISSN: 13858947     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cej.2014.05.002     Document Type: Article

References (29)

1. Shoyele S.A., Cawthorne S. Particle engineering techniques for inhaled biopharmaceuticals. Adv. Drug Deliv. Rev. 2006, 58:1009-1029.
2. Louey M.D., Van Oort M., Hickey A.J. Aerosol dispersion of respirable particles in narrow size distributions produced by jet-milling and spray-drying techniques. Pharm. Res. 2004, 21:1200-1206.
3. Giry K., Péan J.M., Giraud L., Marsas S., Rolland H., Wüthrich P. Drug/lactose co-micronization by jet milling to improve aerosolization properties of a powder for inhalation. Int. J. Pharm. 2006, 321:162-166.
4. Irngartinger M., Camuglia V., Damm M., Goede J., Frijlink H.W. Pulmonary delivery of therapeutic peptides via dry powder inhalation: effects of micronisation and manufacturing. Eur. J. Pharm. Biopharm. 2004, 58:7-14.
5. El-Gendy N., Selvam P., Soni P., Berkland C. Development of budesonide nanocluster dry powder aerosols: processing. J. Pharm. Sci. 2012, 101:3425-3433.
6. Steckel H., Thies J., Müller B.W. Micronizing of steroids for pulmonary delivery by supercritical carbon dioxide. Int. J. Pharm. 1997, 152:99-110.
7. Martin T.M., Bandi N., Shulz R., Roberts C.B., Kompella U.B. Preparation of budesonide and budesonide-PLA microparticles using supercritical fluid precipitation technology. AAPS PharmSciTech. 2002, 3:1-11.
8. Velaga S.P., Berger R., Carlfors J. Supercritical fluids crystallization of budesonide and flunisolide. Pharm. Res. 2002, 19:1564-1571.
9. Bandi N., Wei W., Roberts C.B., Kotra L.P., Kompella U.B. Preparation of budesonide- and indomethacin-hydroxypropyl-β-cyclodextrin (HPBCD) complexes using a single-step, organic-solvent-free supercritical fluid process. Eur. J. Pharm. Sci. 2004, 23:159-168.
10. Steckel H., Pichert L., Müller B.W. Influence of process parameters in the ASES process on particle properties of budesonide for pulmonary delivery. Eur. J. Pharm. Biopharm. 2004, 57:507-512.
11. Lobo J.M., Schiavone H., Palakodaty S., York P., Clark A., Tzannis S.T. SCF-engineered powders for delivery of budesonide. J. Pharm. Sci. 2005, 94:2276-2288.
12. Ruch F., Matijevic E. Preparation of micrometer size budesonide particle by precipitation. J. Colloid Interface Sci. 2000, 229:207-211.
13. Rasenack N., Steckel H., Müller B.W. Micronization of anti-inflammatory drugs for pulmonary delivery by a controlled crystallization process. J. Pharm. Sci. 2003, 92:35-44.
14. Rasenack N., Müller B.W. Micro-size drug particles: common and novel micronization techniques. Pharm. Dev. Technol. 2004, 9:1-13.
15. Chan H.K. Dry powder aerosol delivery systems: current and future research directions. J. Aerosol Med. 2006, 19:21-27.
16. Tang P., Chan H.K., Raper J.A. Prediction of aerodynamic diameter of particles with rough surfaces. Powder Technol. 2004, 147:64-78.
17. Timothy M.C., Jacky A.R., Jeffry D.S., Anthony J.H., Ted B.M. Fundamental effects of particle morphology on lung delivery: predictions of Stokes' Law and the particular relevance to dry powder inhaler formulation and development. Pharm. Res. 2002, 19:239-245.
18. Gerhard S., Martin J.K., Peter B., Ruediger S. Clinical perspectives on pulmonary systemic and macromolecular delivery. Adv. Drug Deliv. Rev. 2006, 58:996-1008.
19. Bosquillon C., Rouxhet P.G., Ahimou F., Simon D., Culot C., Préat V., Vanbever R. Aerosolization properties, surface composition and physical state of spray-dried protein powders. J. Control. Release 2004, 99:357-367.
20. Mohamed F., van der Walle C.F. PLGA microcapsules with novel dimpled surfaces for pulmonary delivery of DNA. Int. J. Pharm. 2006, 311:97-107.
21. Chew N.Y.K., Chan H.K. Use of solid corrugated particles to enhance powder aerosol performance. Pharm. Res. 2001, 18:1570-1577.
22. Reverchon E., Caputo G., De Marco I. Role of phase behavior and atomization in the supercritical antisolvent precipitation. Ind. Eng. Chem. Res. 2003, 42:6406-6414.
23. Chang S.C., Lee M.J., Lin H.M. Role of phase behavior in micronization of lysozyme via a supercritical anti-solvent process. Chem. Eng. J. 2008, 139:416-425.
24. Steckel H., Brandes H.G. A novel spray-drying technique to produce low density particles for pulmonary delivery. Int. J. Pharm. 2004, 278:187-195.
25. Keck C.M., Müller R.H. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenization. Eur. J. Pharm. Biopharm. 2006, 62:3-16.
26. Hu T.T., Zhao H., Jiang L.C., Le Y., Chen J.F., Yun J. Engineering pharmaceutical fine particles of budesonide for dry powder inhalation (DPI). Ind. Eng. Chem. Res. 2008, 47:9623-9627.
27. Chan H.K. Dry powder aerosol drug delivery - opportunities for colloid and surface scientists. Colloid Surf. A: Physicochem. Eng. Aspects 2006, 50:284-285.
28. Kawashima Y., Serigano T., Hino T., Yamamoto H., Takeuchi H. Effect of surface morphology of carrier lactose on dry powder inhalation property of pranlukast hydrate. Int. J. Pharm. 1998, 172:179-188.
29. Chew N.Y.K., Tang P., Chan H.K., Raper J.A. How much particle surface corrugation is sufficient to improve aerosol performance of powders?. Pharm. Res. 2005, 22:148-152.